Pulse Biosciences, Inc.

Pulse Biosciences is a novel bioelectric medicine company that develops and commercializes the nPulse System, a Nanosecond Pulsed-Field Ablation delivery platform. Its portfolio includes the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical settings, the nPulse Cardiac Surgical Clamp designed for surgical treatment of atrial fibrillation, and the nPulse Cardiac Catheter System that provides circumferential ablation in a single treatment cycle. The nPulse Console is a software-enabled platform that accommodates physician-preferred clinical workflows. The company focuses on treating benign lesions of the skin and other soft tissue conditions using its proprietary nanosecond pulsed-field technology.

Pulse Biosciences is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol PLSE. Its shares are traded in US dollars (USD), as the company is headquartered in the United States and reports its financials in USD. The NasdaqCM is a US-based stock exchange that lists smaller-capitalization companies, providing them with access to public capital markets while maintaining listing standards.

Pulse Biosciences operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This industry includes companies that design, manufacture, and sell medical devices, instruments, and supplies used in healthcare settings. As a bioelectric medicine company, Pulse Biosciences focuses on developing innovative ablation technologies that use nanosecond pulsed electric fields to treat medical conditions, particularly in dermatology and cardiac surgery.

Pulse Biosciences is headquartered in Miami, Florida, United States. The company was incorporated in 2014 and was formerly known as Electroblate, Inc. before rebranding to Pulse Biosciences in December 2015. Its location in Miami places it within a major US business hub, and the company serves markets primarily in the United States. The rebranding reflected its strategic shift toward developing nanosecond pulsed-field ablation technology for medical applications.

Pulse Biosciences generates revenue by commercializing its nPulse System and related products, including the nPulse Vybrance Percutaneous Electrode system, nPulse Cardiac Surgical Clamp, nPulse Cardiac Catheter System, and nPulse Console. These devices are sold to healthcare providers such as hospitals, surgical centers, and dermatology clinics. The company's business model focuses on developing innovative bioelectric medicine solutions that address unmet medical needs in soft tissue ablation, particularly for benign skin lesions and cardiac arrhythmias like atrial fibrillation. Revenue is derived from product sales, and the company may also generate income from service contracts and consumables associated with its platforms.